The Deal Features Mark Lebovitch As Top M&A Plaintiffs’ Attorney

May 2012

In its feature article, “The Troika Atop the M&A Plaintiffs’ Bar,”  The Deal magazine prominently profiles BLB&G partner Mark Lebovitch as one of the top three lawyers nationally representing shareholder plaintiffs in M&A litigation.  The article chronicles the story of how Mr. Lebovitch’s practice came to focus on M&A litigation while at BLB&G, primarily fueled by his keen awareness that “the Delaware judges were yearning for someone to litigate on the plaintiffs’ side the way people litigated on the defense side.”  According to Mr. Lebovitch, “I thought if someone worked hard and took real risk, he’d be rewarded.”

While at the firm, Mr. Lebovitch has successfully represented shareholders in several landmark cases, including the litigation involving Caremark Rx, Inc. Merger Litigation, which forced CVS Corporation to increase the consideration offered to Caremark shareholders by over $3 billion.  The article also references his work in challenging the high-profile acquisition of El Paso Corporation by Kinder Morgan, as well as his prosecution of the Pfizer Derivative Litigation, which resulted in a $75 million dedicated fund to support the creation of a “novel regulatory compliance board committee.”  In addition, the article highlights his work representing Dollar General Corporation shareholders (by challenging the terms of a proposed “going-private” offer from Kravis Roberts & Co.) in which he obtained a $40 million settlement for shareholders (with potential for $17 million in additional funds).